Antisense Therapeutics Ltd
ASX:ANP
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
T
|
Tullow Oil PLC
OTC:TUWOY
|
UK |
Antisense Therapeutics Ltd
Other
Antisense Therapeutics Ltd
Other Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Other | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Antisense Therapeutics Ltd
ASX:ANP
|
Other
AU$0
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Recce Pharmaceuticals Ltd
ASX:RCE
|
Other
-AU$186.1k
|
CAGR 3-Years
N/A
|
CAGR 5-Years
36%
|
CAGR 10-Years
N/A
|
|
|
Mayne Pharma Group Ltd
ASX:MYX
|
Other
AU$3.3m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Neuren Pharmaceuticals Ltd
ASX:NEU
|
Other
-AU$37k
|
CAGR 3-Years
-164%
|
CAGR 5-Years
49%
|
CAGR 10-Years
-12%
|
|
|
C
|
Clarity Pharmaceuticals Ltd
ASX:CU6
|
Other
-AU$193.4k
|
CAGR 3-Years
67%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Nyrada Inc
ASX:NYR
|
Other
-AU$407.1k
|
CAGR 3-Years
N/A
|
CAGR 5-Years
15%
|
CAGR 10-Years
N/A
|
|
Antisense Therapeutics Ltd
Glance View
Antisense Therapeutics Ltd. engages in the research and development of novel antisense pharmacceuticals. The company is headquartered in Melbourne, Victoria. The company went IPO on 2001-12-20. The firm is engaged in developing and commercializing antisense pharmaceuticals for unmet markets in rare diseases. The firm's product candidate, ATL1103, is an antisense drug designed to block growth hormone receptor (GHr) expression thereby reducing levels of the hormone insulin-like growth factor-I (IGF-I) in the blood. ATL1103 is in clinical development for acromegaly. The firm's product candidate, ATL1102, is an antisense inhibitor targeting very late antigen 4 (VLA-4), an immune cell molecule. The firm completed a Phase IIa efficacy and safety trial of ATL1102 in multiple sclerosis (MS) patients. The firm is engaged in clinical development of ATL1102 in patients with Duchenne Muscular Dystrophy (DMD). The firm is conducting a Phase II clinical trial of ATL1102 in DMD patients.
See Also
What is Antisense Therapeutics Ltd's Other?
Other
0
AUD
Based on the financial report for Jun 30, 2023, Antisense Therapeutics Ltd's Other amounts to 0 AUD.
